Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVernalis PLC Regulatory News (VER)

  • There is currently no data for VER

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

31 Oct 2014 17:17

RNS Number : 9032V
Vernalis PLC
31 October 2014
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Vernalis plc

 

 

2 Reason for the notification (please tick the appropriate box or boxes):

 

An acquisition or disposal of voting rights

 

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

X

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

3. Full name of person(s) subject to the notification obligation:

 

SFM UK Management LLP

4. Full name of shareholder(s) (if different from 3.):

 

Quantum Partners LP

5. Date of the transaction and date on which the threshold is crossed or reached:

 

30 October, 2014

6. Date on which issuer notified:

 

31 October, 2014

7. Threshold(s) that is/are crossed or reached:

 

Crossed below 3%

 

8. Notified details:

A: Voting rights attached to shares

 

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights

Direct

Indirect

Direct

Indirect

Ordinary 1p Shares

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 GB00B3Y5L754

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

Expirationdate

Exercise/ConversionPeriod

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

 N/A

N/A

N/A

N/A

 N/A

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

Exerciseprice

Expirationdate

Exercise/Conversionperiod

Number of votingrights instrumentrefers to

% of voting rights

 

Contract for

Difference

 N/A

 N/A

 N/A

N/A

Nominal

Delta

 

Below 3%

N/A

 

Total (A+B+C)

 

Number of voting rights

Percentage of voting rights

N/A

Below 3%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

This statement relates to a Contract for Difference ("CFD") held for the account of Quantum Partners LP, a Cayman Islands exempted limited partnership ("Quantum Partners"). SFM UK Management LLP, a subadvisor to Soros Fund Management LLC, serves as investment manager to Quantum Partners and has been granted investment discretion over portfolio investments, including the CFD, held for the account of Quantum Partners.

 

 

Proxy Voting:

 

10. Name of the proxy holder:

 

N/A

11. Number of voting rights proxy holder will cease to hold:

 

N/A

12. Date on which proxy holder will cease to hold voting rights:

 

 N/A

 

13. Additional information:

 

N/A

14. Contact name:

 

Ian Garland, CEO

15. Contact telephone number:

 

0118 938 0015

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLFDMFWFFLSEFS
Date   Source Headline
28th Apr 20177:00 amRNSTotal Voting Rights
26th Apr 20177:00 amRNSServier and Vernalis announce 3 milestones
21st Apr 20177:01 amRNSVernalis receives $2 million milestone payment
21st Apr 20177:00 amRNSFDA Issues Complete Response Letter on CCP-07 NDA
29th Mar 20179:00 amRNSBlock listing Interim Review
6th Mar 20177:00 amRNSNew drug discovery collaboration with Servier
28th Feb 20177:00 amRNSTotal Voting Rights
21st Feb 20177:00 amRNSUnaudited interim results for 6 months to 31/12/16
14th Feb 20177:00 amRNSAchievement of a $3m milestone payment from Corvus
30th Jan 201712:36 pmRNSNotice of Results for Six Months Ended 31/12/2016
21st Dec 20167:00 amRNSFDA accepts CCP-08 NDA for full review
1st Dec 20161:00 pmRNSVernalis Results of Annual General Meeting
1st Dec 20167:00 amRNSAGM Statement
3rd Nov 20164:36 pmRNSHolding(s) in Company
31st Oct 20167:00 amRNSTotal Voting Rights
24th Oct 20169:43 amRNSNotice of Annual Report and AGM
13th Oct 201611:58 amRNSHolding(s) in Company
12th Oct 20164:58 pmRNSDirector/PDMR Shareholding
12th Oct 20164:57 pmRNSDirector/PDMR Shareholding
5th Oct 20162:00 pmRNSHolding(s) in Company
5th Oct 20161:02 pmRNSHolding(s) in Company
30th Sep 20163:55 pmRNSDirector/PDMR Shareholding
29th Sep 20163:00 pmRNSBlock listing Interim Review
29th Sep 20167:00 amRNSResults Announcement for 12 months ended 30/06/16
22nd Sep 20161:43 pmRNSHolding(s) in Company
14th Sep 201610:54 amRNSHolding(s) in Company
13th Sep 201610:34 amRNSNotice of Results
6th Sep 20167:00 amRNSFDA accepts CCP-07 NDA for full review
29th Jul 20167:00 amRNSTotal Voting Rights
26th Jul 201612:53 pmRNSHolding(s) in Company
19th Jul 20167:00 amRNSVernalis Achieves Oncology Milestone with Servier
15th Jul 20167:00 amRNSVernalis Notes RedoxTherapies Acquisition by Juno
8th Jul 20167:00 amRNSVernalis Announce CCP-08 Multiple-Dose Results
7th Jul 20161:47 pmRNSYear-end Trading Update and Notice of Results
30th Jun 20167:00 amRNSTotal Voting Rights
24th Jun 20163:52 pmRNSHolding(s) in Company
9th Jun 20162:58 pmRNSDirector Dealing
31st May 20167:00 amRNSTotal Voting Rights
19th May 20164:11 pmRNSMoxatag Supply Update
16th May 20162:44 pmRNSHolding(s) in Company
12th May 201611:10 amRNSResults of General Meeting
29th Apr 20167:00 amRNSTotal Voting Rights
27th Apr 20164:40 pmRNSHolding(s) in Company
26th Apr 20165:17 pmRNSPosting of Circular and Notice of General Meeting
26th Apr 201611:00 amRNSVernalis plc to raise £40 million in Placing
21st Apr 20162:26 pmRNSSandford Sommer appointed as President & COO in US
14th Apr 20167:00 amRNSVernalis Announce CCP-07 Multiple-Dose Results
13th Apr 20167:00 amRNSVernalis Announce CCP-08 Single-Dose Study Results
31st Mar 20169:00 amRNSTotal Voting Rights
29th Mar 20161:55 pmRNSBlocklisting Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.